Lancashire and South Cumbria
Formulary
Formulary
13 Skin
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
13-05-03 Drugs affecting the immune response
| Abrocitinib Cibinqo® |
|
Formulary
|
Tablets 50mg - for treating moderate to severe atopic dermatitis Tablets 100mg - for treating moderate to severe atopic dermatitis Tablets 200mg - for treating moderate to severe atopic dermatitis |
 NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
| Adalimumab Biosimilars avaliable |
|
Formulary
|
S/C injection 40mg pre-filled syringe, pre-filled pen |
|
MHRA: Tumour necrosis factor alpha inhibitors NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people NIE TA146: Adalimumab for the treatment of adults with psoriasis |
|
| Apremilast Otezla® |
|
Formulary
|
Tablets 10mg, 20mg, 30mg |
|
MHRA: Apremilast (Otezla ▼): risk of suicidal thoughts and behaviour NICE TA419: Apremilast for treating moderate to severe plaque psoriasis NICE TA433: Apremilast for treating active psoriatic arthritis |
|
|
| Azathioprine |
|
Formulary
|
Tablets 25mg, 50mg |
 LSCMMG: Azathioprine and Mercaptopurine shared care guideline |
|
| Baricitinib |
|
Formulary
|
Film-coated tablets 2mg, 4mg
|
|
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis NICE TA926: Baricitinib for treating severe alopecia areata |
|
|
Treatment of atopic dermatitis
Treatment of alopecia areata| Bimekizumab Bimzelx® |
|
Formulary
|
Pre-filled pen/syringe 160mg Usually supplied to patients via a homecare delivery company |
|
NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis |
|
|
| Brodalumab Kyntheum® |
|
Formulary
|
Solution for injection pre-filled syringes 210mg/1.5ml |
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
|
|
| Ciclosporin |
|
Formulary
|
Consultant dermatologist or specilaist initiation only |
|
LSCMMG: Ciclosporin shared care guideline |
|
|
| Deucravacitinib SOTYKTU |
|
Formulary
|
Film coated tablets 6mg
|
|
NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis |
|
|
| Dupilumab Dupixent® |
|
Formulary
|
Pre-filled syringe 300mg/2ml solution for injection
|
|
MHRA: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis |
|
|
| Etanercept Biosimilars avaliable |
|
Formulary
|
S/C injection 50mg pre-filled syringe, pre-filled pen |
|
MHRA: Tumour necrosis factor alpha inhibitors NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
|
|
| Guselkumab Tremfya® |
|
Formulary
|
Solution for injection in pre-filled pen 100mg/1ml |
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
|
|
| Infliximab Biosimilars avaliable |
|
Formulary
|
Intravenous infusion 100mg |
|
MHRA: Tumour necrosis factor alpha inhibitors NICE TA134: Infliximab for the treatment of adults with psoriasis |
|
|
| Lebrikizumab |
|
Formulary
|
NHSE commissioned for children / young adults aged 12-18 years |
|
NICE TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over |
|
|
| Methotrexate |
|
Formulary
|
Consultant dermatologist or specialist initiation only Psoriatic arthritis Methotrexate should be prescribed once weekly as a single dose on the same day each week. If oral methotrexate is prescribed only use the 2.5 mg strength |
|
LSCMMG: Methotrexate shared care guideline |
|
|
| Omalizumab |
|
Formulary
|
Chronic spontaneous urticaria.
|
|
LSCMMG: Omalizumab NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
|
|
Unlicensed use of omalizumab for severe chronic inducible urticarias.| Pimecrolimus 1% Elidel® |
|
Formulary
|
Cream 30g, 60g, 100g |
|
NICE TA82: Tacrolimus and pimecrolimus for atopic eczema |
|
| Risankizumab Skyrizi® |
|
Formulary
|
solution for injection pre-filled syringes, solution for injection pre-filled pen 150mg/mL
|
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
|
|
NICE TA888 Risankizumab for previously treated moderately to severely active Crohn's disease - see link below| Ritlecitinib |
|
Formulary
|
Severe alopecia areata |
|
BAD: Professional guidance supplementary to NICE TA958 NICE TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over |
|
|
| Secukinumab Cosentyx® |
|
Formulary
|
150mg pre-filled syringe |
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people |
|
|
for palmoplantar psoriasis - off-label use| Tacrolimus Protopic® |
|
Formulary
|
Ointment 0.03%, 0.1% 30g, 60g Psoriasis. |
|
MHRA: Tacrolimus ointment (Protopic): possible risk of malignancies including lymphomas and skin cancers NICE TA82: Tacrolimus and pimecrolimus for atopic eczema |
|
|
| Tildrakizumab Ilumetri® |
|
Formulary
|
Solution for injection pre-filled syringes 100mg/1ml |
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
|
|
| Tralokinumab Adtralza® |
|
Formulary
|
Pre-filled syringe 150 mg solution for injection - for treating moderate to severe atopic dermatitis - see link below |
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
|
| Ustekinumab Stelara® |
|
Formulary
|
Injection 45mg, 90mg pre-filled syringe |
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
|
|
Links
-
- BAD: Professional guidance supplementary to NICE TA958
- Efalizumab (Raptiva): Recommendation to suspend Marketing Authorisation as risks outweigh benefits
- LSCMMG Shared Care Guideline - Azathioprine and Mercaptopurine
- LSCMMG Shared Care Guideline - Ciclosporin
- LSCMMG Shared Care Guideline - Methotrexate
- LSCMMG: Azathioprine and Mercaptopurine shared care guideline
- LSCMMG: Ciclosporin shared care guideline
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Methotrexate shared care guideline
- LSCMMG: Omalizumab
- LSCMMG: Primary Care Constipation Guidelines
- LSCMMG: Psoriasis in adults: LSCMMG Biologic and High Cost Drug Commissioning Pathway
- MHRA Drug Safety Update April 2014: Tumour necrosis factor alpha inhibitors
- MHRA Drug Safety Update Jan 2017: Apremilast (Otezla): risk of suicidal thoughts and behaviour
- MHRA Drug Safety Update: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
- MHRA Drug Safety Update: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
- MHRA Drug Safety Update: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
- MHRA Drug Safety Update: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
- MHRA Drug Safety Update:Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Apremilast (Otezla ▼): risk of suicidal thoughts and behaviour
- MHRA: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Tacrolimus ointment (Protopic): possible risk of malignancies including lymphomas and skin cancers
- MHRA: Tuberculosis risk—screen patients before starting treatment
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Tumour necrosis factor alpha inhibitors
- MHRA: Tumour necrosis factor alpha inhibitors
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG153: Psoriasis: assessment and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
- NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
- NICE TA103:Etanercept and efalizumab for the treatment of adults with psoriasis
- NICE TA134: Infliximab for the treatment of adults with psoriasis
- NICE TA134: Infliximab for the treatment of adults with psoriasis
- NICE TA134: Infliximab for the treatment of adults with psoriasis
- NICE TA134: Infliximab for the treatment of adults with psoriasis
- NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
- NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA329 :Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
- NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
- NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
- NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
- NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
- NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
- NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
- NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
- NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
- NICE TA433: Apremilast for treating active psoriatic arthritis
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
- NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
- NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
- NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
- NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
- NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
- NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
- NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
- NICE TA596:Risankizumab for treating moderate to severe plaque psoriasis
- NICE TA648:Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
- NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
- NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
- NICE TA701: Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)
- NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
- NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis
- NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis
- NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
- NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
- NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
- NICE TA751:Dupilumab for treating severe asthma with type 2 inflammation
- NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814 : Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
- NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
- NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
- NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
- NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
- NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis
- NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis
- NICE TA926: Baricitinib for treating severe alopecia areata
- NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis
- NICE TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
- NICE TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
- NICE768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NIE TA146: Adalimumab for the treatment of adults with psoriasis
- TA433: Apremilast for treating active psoriatic arthritis
- UKMI Q&A: Can mothers breastfeed while taking azathioprine?
- UKMI Q&A: What is the clinical significance of the interaction between methotrexate and penicillins? (Oct13)